TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
ALNY

Alnylam Pharmaceuticals Inc

Healthcare · Biotechnology

256.00$ +2.6% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Income Statement

Alnylam Pharmaceuticals Inc (ALNY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 1,291 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement ALNY
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
751 440 494 660 501 593 594 774 1,249 1,097 1,167 1,291 4,804
84 86 66 69 86 103 71 143 197 268 211 298 974
666 354 428 591 415 490 523 631 1,052 829 956 993 3,830
253 272 261 294 271 300 265 324 359 372 365 413 1,509
199 198 211 248 221 295 240 323 322 325 323 348 1,318
452 470 472 543 492 596 505 647 684 698 687 761 2,830
214 -116 -43 49 -77 -105 18 -16 368 132 269 231 1,000
31 31 35 33 34 39 39 40 44 129 69 82 325
151 -138 -64 -11 -109 -194 -42 -35 239 161 222 178 800
3.0 0.2 2.3 5.7 2.9 -110 16 31 -12 -25 -16 13 -40
148 -138 -66 -17 -112 -84 -57 -66 251 186 206 164 808
195 -93 -15 37 -60 -141 11 19 297 304 304 245 1,150

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?